Joel Schlessinger M.D.

The Food and Drug Administration recently approved COSENTYX® (secukinumab) for the treatment of moderate to severe plaque psoriasis. Joel Schlessinger MD and his staff at the Advanced Skin Research Center participated in a successful clinical study with this drug. Their participation was vital in the approval of COSENTYX®. The study conducted by Joel Schlessinger MD […]

Joel Schlessinger MD and his clinic at Skin Specialists P.C. of Omaha, Nebraska have been participating in an ongoing study involving the use of the antibody brodalumab for the use of treating patients with moderate to severe plaque psoriasis. Phase 3 of the AMAGINE-2 study has just been completed, and they are pleased to announce […]

In a study published by the British Journal of Dermatology, researchers found Tofacitinib to be an effective treatment for moderate to severe chronic plaque psoriasis. Joel Schlessinger MD and his staff at the Advanced Skin Research Center were an integral part of the study, conducting research over a 56-week period. The study conducted by Joel […]

Thanks in part to a study performed by Dr. Joel Schlessinger, a new rosacea drug has been approved by the United States Food and Drug Administration. Alpha-2 adrenergic agonist brimonidine, also known as Mirvaso, was recently approved by the FDA to treat facial redness in rosacea patients. This is the first topical gel treatment specifically […]

As Chief Editor of Cosmetic Surgery, Joel Schlessinger MD is dedicated to providing education for practices. Since its inception, Joel Schlessinger MD has contributed his knowledge and expertise to Practical Dermatology, a premiere publication that provides coverage of major cosmetic advancements and practice management for dermatology. In his article “Toward Innovation and Collaboration,” Joel Schlessinger […]